Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Inclusion Criteria: * Deemed resectable or borderline resectable at baseline, confirmed by MDT evaluation at diagnosis. * Previously untreated and pathologically confirmed Stage IIB to select \[i.e.N2\] Stage IIIB by AJCC v8. * Nodal status confirmed with whole body FDG-PET and biopsy via endobronchial ultrasound, mediastinoscopy, or thoracoscopy. * Mandatory brain MRI. * EGFR and ALK wild-type. * Medically operable: adequate cardiac and lung function to undergo resection. * Participant must be ≥ 18 years, at the time of screening. * Histologically or cytologically documented NSCLC. * Minimum life expectancy of 12 weeks. * Minimum body weight of 30 kg. * Male and female participants must be willing to use acceptable methods of contraception. * Female participants of childbearing potential must have negative pregnancy test. Exclusion Criteria: * Unresectable NSCLC confirmed by MDT evaluation at baseline * Stage IIIC patients * Participants whose planned surgery at enrollment is a wedge resection * Known EGFR mutation or ALK translocation * Participants contraindicated for surgical intervention due to comorbid conditions * Participants who are allergic to study intervention. * Participants with more than one primary tumour. * Known active hepatitis infection, positive HCV antibody, HBsAg or HBV core antibody (anti-HBc), at screening. * Female participants who are pregnant or breastfeeding. * Judgement by the investigator that the participant should not participate in the study. * Previously infected or tested positive for human immunodeficiency virus.